Three Bridge Wealth Advisors’s Immunome IMNM Stock Holding History

Three Bridge Wealth Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$823K	Hold	37,615	–	–	0.23%	45
2025 Q4	$808K	Hold	37,615	–	–	0.21%	44
2025 Q3	$440K	Hold	37,615	–	–	0.11%	64
2025 Q2	$350K	Hold	37,615	–	–	0.09%	80
2025 Q1	$253K	Buy	37,615 +10,000	+36%	+$95.9K	0.09%	76
2024 Q4	$293K	Buy	+27,615	New	+$334K	0.1%	75

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Three Bridge Wealth Advisors's IMNM Position: Q1 2026 in Review

Three Bridge Wealth Advisors held its Immunome (IMNM) position steady in Q1 2026 at 37,615 shares worth $823K. The position accounts for 0.23% of the portfolio, ranked #45.

Three Bridge Wealth Advisors first reported a position in IMNM in Q4 2024 and has held it in 6 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

Three Bridge Wealth Advisors held 37,615 shares of Immunome worth $823K as of Q1 2026.
Three Bridge Wealth Advisors left its Immunome share count unchanged in Q1 2026.
Immunome made up 0.23% of Three Bridge Wealth Advisors's portfolio in Q1 2026, its #45 holding.
Three Bridge Wealth Advisors first reported a position in Immunome in Q4 2024 and has held it in 6 quarters since.
200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Three Bridge Wealth Advisors's 13F filing for Q1 2026, filed 12 May 2026.